TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Upper limb spasticity~* Time since stroke greater than 3 months~* Need for 400 U Botulinum toxin type A~Exclusion Criteria:~* Body weight below 50kg~* Fixed contractures of the upper limb~* Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin Type A~* Infection at the injection site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DB IncobotulinumtoxinA (Xeomin) (400 U) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
- DB Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Augmenting Exposure Therapy With an N-Methyl-D-Aspartate (NMDA) Agonist for Panic Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Principal diagnosis of panic disorder~Exclusion Criteria:~* History of psychotic disorders or bipolar disorder~* Substance dependence~* Pregnant or breastfeeding~* History of a medical condition that may increase the risks of taking the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* Aged between 18 and 70 years~* Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment~* Willing to adhere to the study protocol~Exclusion Criteria:~* Being pregnant~* Acute cytolysis in the last three months before enrollment~* Any vaccination before or during the month preceding enrollment~* Any Intolerance or allergy to any component of the vaccine~* Ongoing opportunistic infection~* Hematological disorder~* Cancer~* Unexplained fever the week before enrollment~* Immunosuppressive or immunomodulating treatment in the last six months~* Liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
- 20 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male, between 30 and 50 years~* HIV-1 RNA \< 50 copies/mL on screening visit~* on Atripla continuously for ≥6 months preceding the screening visit~* Have a HIV genotype prior to starting cART with Atripla with no known resistance to any of the study agents at any time in the past including, but not limited to RT mutations K65R, K101E/P, E138G/K/Q/R, Y181C/I/V, M184V/I and H221Y~* Negative TPHA or VDRL \< 12 months prior to the screening visit~* no signs of an acute or chronic hepatitis C infection within the past 12 months before screening as defined in the Dutch guideline (Arends et al. Neth J Med 2011)~* No subjective neurocognitive complaints in the preceding 12 months~* willingness to take Eviplera together with food according to the manufacturer's prescriptions.~* Estimated glomerular filtration rate ≥50 mL/min (Cockcroft-Gault formula) on last routine measurement during outpatient clinic~* able to understand and comply to study procedures and to provide written informed consent~Exclusion Criteria:~* Non-native Dutch speakers~* Proven major depression through psychiatric consultation within the past year or on anti-depressant drugs (SSRI or TCA)~* Active or known from medical history past CNS opportunistic infections~* History of proven neurologic disease (e.g. multiple sclerosis, brain tumor, cerebrovascular event, etc)~* Active psychiatric disorders classified according to the DMS V criteria~* History or evidence of alcohol or drug abuse defined according to DSM V criteria~* TSH within normal reference values on last routine measurement during outpatient clinic~* Contraindications for undergoing an MRI; a pacemaker or metallic devices/foreign bodies in situ, proven claustrophobia.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (Type: ACTIVE_COMPARATOR): patients switching from Atripla to Eviplera
- Control (Type: NO_INTERVENTION): patients remaining on Atripla

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Follow-Up of Rotator Cuff Tear Patients Treated With Integrated Complementary and Alternative Medicine

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who had been hospitalized with symptoms of shoulder pain at Haeundae Jaseng Korean Medicine Hospital, Jaseng Korean Medicine Hospital, Bucheon Jaseng Korean Medicine Hospital and Daejeon Jaseng Korean Medicine Hospital from Jan 2015 to Mar 2020.~* Patients diagnosed with 'Rotation Cuff Tear' finding of the EMR imaging (T2-weighted MRI scan of Shoulder~* Patients who had been hospitalized more than 3 days~* Patients who are within age from 19 to 70~Exclusion Criteria:~* Patients who are hospitalized by traffic accident~* Patients who are diagnosed other serious shoulder injury that can cause shoulder pain(tumor of shoulder, acute fracture and dislocation of shoulder)~* Patients who had treated shoulder pain at Haeundae Jaseng Korean Medicine Hospital, Jaseng Korean Medicine Hospital, Bucheon Jaseng Korean Medicine Hospital and Daejeon Jaseng Korean Medicine Hospital in recent 6 months.~* Patients who are considered impossible to attend survey by investigators.

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Target lesion(s) must be located in a native epicardial vessel with visually estimated diameter between \>= 2.25 mm and \<= 4.25 mm and a lesion length \<= 32 mm~* The target lesion(s) must be in a major artery or branch with a visually estimated stenosis of \>= 50% and \< 100% with a thrombolysis in myocardial infarction (TIMI) flow of \>= 1~* Non-study, percutaneous intervention for lesions in a non-target vessel is allowed if done \>= 90 days prior to the index procedure (subjects who received brachytherapy will be excluded from the trial)~Exclusion Criteria:~* Located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and \> 20% stenosed lesion by visual estimation) arterial or saphenous vein graft~* Lesion involving a bifurcation \>= 2 mm in diameter or ostial lesion \> 50% stenosed by visual estimation or side branch requiring predilatation~* Located in a major epicardial vessel that has been previously treated with brachytherapy~* Located in a major epicardial vessel that has been previously treated with percutaneous intervention \< 9 months prior to index procedure~* Total occlusion (TIMI flow 0), prior to wire passing~* The target vessel contains thrombus~* Another significant lesion (\> 40% diameter stenosis \[DS\]) is located in the same epicardial vessel as the target lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): XIENCE V® Everolimus Eluting Coronary Stent System
- 2 (Type: ACTIVE_COMPARATOR): TAXUS® EXPRESS2™Paclitaxel Eluting Coronary Stent System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral or unilateral cataract undergoing phacoemulsification and intraocular lens (IOL) implantation at Soonchunhyang University Hospital between January 2014 and January 2015~* Patients with mild to moderate dry eye (level 1 or 2) based on the dry eye severity scale adopted by the Dry Eye Workshop (DEWS) report and who used only artificial tears occasionally~Exclusion Criteria:~* Presence of any complications after cataract surgery such as cystoid macular edema~* Patients using any topical eye drops on a regular basis~* Treatment history of dry eye beyond artificial tears~* Any ocular surgery within the prior 6 months~* Contact lens wear~* Serious ocular surface disease (e.g., Sjögren's syndrome, ocular pemphigoid, conjunctival scarring, chemical injury)~* Eyelid or lacrimal disease~* Use of concomitant medications that could cause dry eye and allergy to any of the study medications

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Diqufosol (Type: ACTIVE_COMPARATOR): 3% Diquafosol Tetrasodium Ophthalmic Solution
- Hyaluronate (Type: PLACEBO_COMPARATOR): 0.1% Sodium Hyaluronate Ophthalmic Solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female outpatients, age 18-75 years;~2. Presence of current DSM-IV nicotine dependence and PG for at least 6 months duration;~3. Stable psychotropic drug dose for a period of at least 3 months prior to study entry;~4. Completion of complete blood count, urinalysis, liver function tests, thyroid function tests, and pregnancy test with no evidence of significant lab abnormalities;~5. Signed informed consent~Exclusion Criteria:~1. Subjects who are currently receiving individual or group therapy specifically for nicotine dependence or PG symptoms;~2. Currently receiving pharmacotherapies for either nicotine dependence or pathological gambling;~3. Subjects who have started attending Gamblers Anonymous within the 3 months prior to study initiation;~4. Subjects who have an unstable and significant medical illness;~5. Current clinically significant suicidality (score or 3 or 4 on item 3 of the Hamilton Depression Rating Scale) or any other disorder requiring immediate intervention;~6. Lifetime history of bipolar disorder type I or II, dementia, or psychotic disorder;~7. Current (past 12 months) DSM-IV substance abuse or dependence (except nicotine dependence);~8. Borderline or antisocial personality disorder based on the SCID-II;~9. Positive urine drug screen at screening;~10. Asthma (given possible worsening of asthma due to NAC);~11. Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent;~12. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential; and~13. Previous treatment with NAC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- N Acetyl Cysteine (Type: EXPERIMENTAL): The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Variations in Palatability and Portion Size of Vegetables on Meal Intake of Preschool Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Children who are enrolled in a scheduled classroom of the designated childcare centers~Exclusion Criteria:~* Children who are allergic to any of the foods served~* Children whose diets exclude any of the foods served~* Children who will not be present at the childcare center for all of the scheduled study days

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Standard Palatability and Standard Portion Size (Type: EXPERIMENTAL): Vegetables with Standard Palatability and Standard Portion Size
- Standard Palatability and Larger Portion Size (Type: EXPERIMENTAL): Vegetables with Standard Palatability and Larger Portion Size
- Enhanced Palatability and Standard Portion Size (Type: EXPERIMENTAL): Vegetables with Enhanced Palatability and Standard Portion Size
- Enhanced Palatability and Larger Portion Size (Type: EXPERIMENTAL): Vegetables with Enhanced Palatability and Larger Portion Size

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* Subject not at LDL-C goal~* History of statin intolerance~* Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes~* Poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Atorvastatin 20 mg => Placebo (Type: OTHER): Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
- Part A: Placebo => Atorvastatin 20 mg (Type: OTHER): Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
- Part B: Ezetimibe (Type: ACTIVE_COMPARATOR): Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
- Part B: Evolocumab (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
- Part C: Open-label Evolocumab (Type: EXPERIMENTAL): Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18-55 with a primary diagnosis of nonpsychotic uni-polar depression~Exclusion Criteria:~* Current co-morbid psychiatric disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): SPD489
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients who had been hospitalized in an acute care hospital for two or more days within the past 90 days;~* residents of a nursing home or long-term care facility;~* recipients of recent intravenous antibiotic therapy, chemotherapy or wound care within the past 30 days;~* or patients who attended a hospital or hemodialysis clinic.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PSI II (Type: None): PSI less than 70 or equal to 70
- PSI III (Type: None): PSI 70-90
- PSI IV (Type: None): PSI 90-130
- PSI V (Type: None): PSI more than 130

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years old or above~2. Participants have to control the birth for example, condom method, intrauterine device method before participate in the research at least 1 month until 6 months after research finish.~3. being diagnosed acne vulgaris by dermatologist in mild to moderate degree based on Investigators' Global Assessment scale of FDA~Exclusion Criteria:~1. Use oral or injected antibiotics or other oral medicine treating acne for example, isotretinoin, oral contraceptives, or spironolactone group during 4 weeks before participate this research~2. Have other active skin diseases at face during 2 weeks before participate the research~3. Allergic to adapalene gel and moisturizer~4. Have severe or uncontrolled underlying diseases~5. Getting pregnant or during breast feeding~6. Other types of acne(not acne vulgaris)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adapalene gel (Type: PLACEBO_COMPARATOR): Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face
- Adapalene gel with placebo moisturizer (Type: PLACEBO_COMPARATOR): Morning~* Wash face by prepared facial foam and dry their face~* Apply placebo cream all over the face~Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face~* Apply placebo cream all over the face
- Adapalene gel with Eucerin (Type: ACTIVE_COMPARATOR): Morning~* Wash face by prepared facial foam and dry their face~* Apply Eucerin cream all over the face~Evening~* Wash face by prepared facial foam and dry your face~* Apply adapalene gel all over the face~* Apply Eucerin cream all over the face

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete